JP6043923B2 - Inhibitors of blood triglycerides associated with dietary intake - Google Patents

Description

The present invention relates to a blood neutral fat elevation inhibitor accompanying dietary intake, characterized by containing a processed barley leaf product.

In recent years, so-called lifestyle-related diseases such as dyslipidemia and diabetes have increased. In particular, dyslipidemia requires attention because it progresses to arteriosclerosis, myocardial infarction, cerebral infarction and the like as it progresses.

Dyslipidemia is a condition in which the lipid contained in the blood is excessive or insufficient, specifically, a condition in which LDL cholesterol or neutral fat is excessive, or a condition in which HDL cholesterol is insufficient. Dyslipidemia is a dangerous disease that rarely accompanies pain and other subjective symptoms and is often left unattended, and may develop into a serious disease such as arteriosclerosis without notice. It is.

One of the main causes of dyslipidemia is an increase in blood triglycerides due to excessive consumption of oily foods. In order to prevent this, it is important to improve lifestyle habits, such as refraining from oily foods and exercising continuously, but it is easy for busy modern people who cannot afford to eat and exercise. is not.

In order to solve this problem, various substances that can be used as an inhibitor of blood neutral fat elevation have been developed. Examples of the blood neutral fat increase inhibitor include, for example, indigestible dextrin (Non-patent Document 1), plant-derived and cellulose and lignin as main components, and the cellulose and lignin exhibit a binding state in the plant body. Maintained edible dietary fiber (Patent Document 1), Koju's solvent extract (Patent Document 2), Devil's claw extract (Patent Document 3), high water-soluble extract obtained from fermented decomposition products of raw materials including soybean Molecular substance (Patent Document 4), Perilla fruitess dry substance concentration 90-99.9 vol% ethanol aqueous solution extract (Patent Document 5), Anthocyanin-containing potato (Patent Document 6), Yunnan tea extract ( Patent Document 7), globin proteolysate (Patent Document 8), organic solvent or water extract of Alphabacca (Patent Document 9), epithea flagarin 3-O- Rate and the like are known (Patent Document 10).

Japanese Patent Laid-Open No. 06-340532 JP 2009-275026 A JP 2009-132634 A JP 2008-088151 A JP 2007-246471 A JP 2007-161689 A JP 2007-099651 A No. 2006/038327 JP 09-059168 A JP 2009-114079 A

“Inhibition of postprandial neutral fat increase and safety of long-term intake and overdose of mixed tea beverage containing indigestible dextrin”, Journal of Japanese Society of Food Chemistry, 2009, 16 (1), p20-27

  Among them, blood neutral fat elevation inhibitor containing a lot of dietary fiber such as indigestible dextrin and edible dietary fiber mainly composed of cellulose and lignin, not only suppress the rise of blood neutral fat, It can be supplemented with dietary fiber, which is often deficient in daily life, so it is suitable for the lifestyle of modern people and can be said to be an excellent blood neutral fat elevation inhibitor.

As described above, many blood neutral fat elevation inhibitors containing a large amount of dietary fiber have been developed. However, these have a relatively weak blood neutral fat elevation-inhibiting action, which is not always sufficient for some people. There was a problem that an effective effect could not be obtained. The present invention has been made to solve the above-described problems, and suppresses blood neutral fat elevation, which is superior to conventional blood neutral fat elevation inhibitors containing a large amount of dietary fiber. The purpose is to provide an agent.

As a result of diligent studies to achieve the above-mentioned object, the present inventors have found that barley leaves have an excellent blood neutral fat increase-inhibiting action among materials containing a large amount of dietary fiber. It came to complete. That is, the blood neutral fat increase inhibitor due to dietary intake of claim 1 of the present invention is characterized by containing a dry powder of the leaves of barley, the blood neutral fat due to dietary intake It is a rise inhibitor.

Blood neutral fat increase inhibitor due to dietary intake according to claim 2, in blood neutral fat increase inhibitor due to dietary intake of claim 1, the blood neutral fat due to dietary intake The blood neutral fat accompanying dietary intake according to claim 1, wherein the amount of dry powder of barley leaves in the rise inhibitor is 0.01 to 100% by mass in terms of dry mass. It is a rise inhibitor.

The blood neutral fat elevation inhibitor of the present invention contains a processed product of barley leaves. Here, the processed barley leaf product exhibits a blood neutral fat increase inhibitory action superior to that of a blood neutral fat increase inhibitor containing a large amount of conventional dietary fiber. Therefore, by using the blood neutral fat increase inhibitor of the present invention, even if the conventional blood neutral fat increase inhibitor has not been able to sufficiently obtain the effect, the blood neutral fat There is an effect that an increase suppressing effect can be expected. In addition, it does not specifically limit regarding the form of this invention, It can use as food-drinks, cosmetics, pharmaceuticals, etc. as it is or adding various components.

  Hereinafter, embodiments of the present invention will be described. In addition, this invention is not limited by description of the below-mentioned embodiment, A various change is possible within the range of description in a claim.

  The processed barley leaf product described in the present invention refers to a processed barley leaf processed by a conventional processing method. Specifically, the barley leaves are processed by processes such as washing, cutting, pulverization, drying, heat treatment, extraction, and juice extraction. The processing method may be a processing method including only a single process, or may be a processing method combining a plurality of processes. As a processing method combining a plurality of processes, for example, a processing method of performing each process of drying, coarse pulverization, heat treatment, and fine pulverization after blanching a barley leaf. The barley leaf processed product used in the present invention is not particularly limited, but preferably, a barley leaf dry powder or barley leaf extract is used, and more preferably, barley leaf extract. Leaf dry powder is used.

  The dry powder of barley leaves used in the present invention is not particularly limited, and normally available dry powder of barley leaves is used.

  Although it does not restrict | limit especially as a manufacturing method of the dry powder of the barley leaf used for this invention, For example, it manufactures by the method as disclosed by patent 3277181.

The barley leaf extract used in the present invention is an extract obtained from raw materials by an extraction process using various extraction solvents, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, Or all of these crudely purified products and purified products are included. The barley leaf extract may be subjected to treatments such as dilution, concentration, drying, purification, and squeezing according to conventional methods.

Examples of the extraction solvent used in the present invention include water, lower monohydric alcohols (such as methyl alcohol and ethyl alcohol), liquid polyhydric alcohols (such as glycerin and 1,3-butylene glycol), lower esters (such as ethyl acetate), Ethers (diethyl ether etc.), acetonitrile, etc. are mentioned, These 1 type or 2 types or more can be used in combination.

The extraction treatment performed in the present invention is not particularly limited and can be performed according to a conventional method, and any apparatus can be used at room temperature or under reflux heating. After eluting soluble components by extraction treatment, an extract of barley leaves can be obtained by removing the extraction residue by filtration.

The blood neutral fat elevation inhibitor of the present invention can be used as it is or as various foods, cosmetics, pharmaceuticals and the like with various components added.

  The aforementioned cosmetics can be provided by being processed into various forms such as lotions, emulsions, gels, creams, ointments and the like. Moreover, it can utilize as cosmetics, a pharmaceutical, a quasi-drug, etc. Specifically, it is used as a lotion, cosmetic cream, milky lotion, cream, pack, hair tonic, hair cream, shampoo, hair rinse, treatment, body shampoo, facial cleanser, soap, foundation, hair restorer, aqueous ointment, spray, etc. be able to.

  Examples of the aforementioned pharmaceutical products include pharmaceutical products that are molded into powder, granular, granular, liquid, tablet, capsule, caplet, soft capsule, tablet, rod, plate, block, pill, etc. Can be offered as.

  The amount of dry powder or extract of barley leaves that can be formulated as a blood triglyceride increase inhibitor, as long as it has a blood triglyceride increase inhibitory effect, it can be used in various conditions such as the dosage form to be used and the target of use. Accordingly, the blending amount can be appropriately set in a wide range. Preferably, the amount of dry powder or extract of barley leaves is 0.01 to 100% by mass, more preferably 0.1 to 80% by mass in terms of dry mass.

  The amount of dry powder or extract of barley leaves that can be added to cosmetics as a blood neutral fat increase inhibitor is various as long as it has an effect of suppressing blood neutral fat increase, Depending on the conditions, the blending amount can be appropriately set in a wide range. Preferably, the amount of dry powder or extract of barley leaves in cosmetics is 0.0001% by mass to 10% by mass, more preferably 0.001% by mass to 5% by mass in terms of dry mass. Is done.

Examples of the present invention will be described below, but it is needless to say that the present invention described in the claims is not limited to the examples.

(Example 1: Suppression of blood neutral fat elevation 1)
In order to confirm the inhibitory action of barley leaves on blood triglycerides, rats were tested for oil loading. In Example 1, the case where oil was loaded immediately after administration of the test substance was examined. In addition, as a comparative example, an indigestible dextrin known as a blood neutral fat elevation inhibitor was used. Hereinafter, a specific measurement method will be described.

(Experimental animal)
As test animals, 9-week-old male SD rats (Kudo Co., Ltd., hereinafter abbreviated as “rats”) were used. Rats were fasted on the day before the test, and the blood triglyceride level of each rat was measured on the day of the test. Based on the measured values, the group was divided into 3 groups of 6 per group so that the average blood triglyceride level per group was almost uniform.

(Preparation of lipid emulsion)
A lipid emulsion was prepared as an oil to be loaded on rats as follows. In the lipid emulsion, a solution was prepared using distilled water so that soybean oil was 200 mg / mL, lecithin (made of eggs) was 12 mg / mL, and glycerin was 22.5 mg / mL, and this was used as a lipid emulsion. . The lipid emulsion was prepared using an ultrasonic homogenizer or vortex.

(Preparation and administration of test substance)
The dried powder of barley leaves (Toyo Shinyaku Co., Ltd.) was suspended using distilled water so as to be 200 mg / mL to obtain Test Solution 1. This test solution 1 was orally administered by gavage at 10 mL / kg to one group of rats, and immediately after that, the lipid emulsion was gavaged at 10 mL / kg (Test group 1).

Moreover, the indigestible dextrin was dissolved so that it might become 200 mg / mL using distilled water, and it was set as the comparison solution 1. This comparative solution 1 was orally administered by gavage at 10 mL / kg to another group of rats, and immediately after that, the lipid emulsion was gavaged by 10 mL / kg (Comparative Group 1).

In addition, 10 mL / kg of distilled water (control solution 1) was orally administered by gavage to the remaining 1 group of rats, and then 10 mL / kg of the lipid emulsion was immediately orally administered (control group 1).

(Measurement of blood triglyceride level)
Rats were bled before administration and 2, 3, and 4 hours after administration, and blood neutral fat levels were measured. The blood neutral fat value was measured using Triglyceride E-Test Wako (Wako Pure Chemical Industries, Ltd.). The measurement results (average values) are shown in Table 1.

From the results in Table 1, in test group 1 to which barley leaves were administered, an increase in blood neutral fat accompanying lipid emulsion administration was suppressed as compared to control group 1 to which this was not administered. Furthermore, it can be seen that in test group 1, an increase in blood neutral fat is suppressed as compared with comparative group 1 to which indigestible dextrin, which is known as a blood neutral fat increase inhibitor, is added.

(Example 2: Suppression of blood neutral fat elevation 2)
In order to confirm the blood neutral fat increase inhibitory action by barley leaves, Example 2 examined the case where the test substance and oil were mixed and administered. In addition, as a comparative example, an indigestible dextrin known as a blood neutral fat elevation inhibitor was used. Hereinafter, a specific measurement method will be described.

(Experimental animal)
As test animals, 7-week-old male SD rats (Kudo Co., Ltd., hereinafter referred to as “rats”) were used. Next, as in Example 1, each group was divided into 3 groups of 6 animals so that the average blood triglyceride level per group was almost uniform.

(Preparation and administration of administration liquid)
Test solution 2 was prepared by mixing barley leaf powder (Toyo Shinyaku Co., Ltd.) at 100 mg / mL and corn oil at 100 mg / mL using a 5% gum arabic aqueous solution. This test solution 2 was orally administered to a group of rats by 20 mL / kg (test group 2).

Further, using a 5% aqueous gum arabic aqueous solution, mixing was performed so that the indigestible dextrin was 100 mg / mL and the corn oil was 100 mg / mL to obtain Comparative Solution 2. This comparative solution 2 was orally administered 20 mL / kg orally to another group of rats (Comparative Group 2).

In addition, a control solution 2 was prepared by mixing corn oil at 100 mg / mL with a 5% gum arabic aqueous solution. This control solution 2 was orally administered 20 mL / kg orally to the remaining one group of rats (control group 2).

Rats were bled before administration and 3 and 4 hours after administration, and blood triglyceride levels were measured in the same manner as in Example 1. The measurement results (average values) are shown in Table 2.

From the results of Table 2, even when the test substance was mixed with oil and administered, the test group 2 to which barley leaves were administered compared to the control group 2 to which the barley leaf was not administered, and the blood accompanying corn oil administration The increase in neutral fat was suppressed. Further, even when the test substance is mixed with oil and administered, the test group 2 is more neutral in blood than the comparative group 2 to which indigestible dextrin known as a blood neutral fat elevation inhibitor is added. It turns out that the rise in fat is suppressed.

  From the above results, the blood neutral fat elevation inhibitor characterized by containing a processed barley leaf product was superior to the conventional blood neutral fat elevation inhibitor containing a large amount of dietary fiber. It was found to show an effect of suppressing blood neutral fat elevation.

The blood neutral fat elevation inhibitor of the present invention, that is, the blood neutral fat elevation inhibitor characterized by containing a processed product of barley leaves, is a blood neutral fat containing a large amount of conventional dietary fiber. Compared to an increase inhibitor, it exhibits an excellent inhibitory effect on blood neutral fat elevation. Food and drink such blood neutral fat increase inhibitor of the present invention, by adding to cosmetics or pharmaceutical compounds, to obtain an excellent food product such that indicates the blood neutral fat increase inhibitory effect, cosmetics or pharmaceutical compounds it can.

Claims (1)

A method for suppressing the increase in blood neutral fat, characterized by comprising dry powder of barley leaves as an active ingredient, suspending dry powder of barley leaves in water and ingesting at the same time as a meal (medical action Except) .